1. The EBMT Handbook. Haemopoietic Stem Cell Transplantation. The revised 2012 Edition. Editors: J. Apperley, E. Carreras, E. Gluckman, T. Masszi.
2. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Copyright 2008 © Children’s Oncology Group. www.survivorshipguidelines.org. Version 3. October 2008.
3. HCT Quick Reference Guidelines. Transplant Consultation and Posttransplant Care. Long-term survival guidelines. National Marrow Donor Program.
4. Recommended screening and preventive practices for long-term survivors after hematopoietic stem cell transplantation; Center for International Blood and Marrrow transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT). Co-published in Biol Blood Marrow Transplant, 2012; 18(3): 337-341; and Hematol Oncol Stem Cell Ther, 2012; 5(1): 1-30.
5. Armenian SH, Kremer LC, Sklar C. Approaches to reduce the long-term burden of treatment-related complications in survivors of childhood cancer. Am Soc Clin Oncol Educ Book. 2015:196-204.
6. Румянцев А.Г., Масчан А.А. Трансплантация гемопоэтических стволовых клеток у детей. Руководство для врачей. М.: МИА, 2003.
7. Duncan CN, Majhail NS, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantationfor relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant.2015 Jan;21(1):151-8.
8. Madanat-Harjuoja LM, Valjento S, Vettenratnta K, et al. Pulmonary function following allogeneic stem cell transplantation in childhood: a retrospective cohort study of 51 patients. Pediatr Transplant. 2014 Sep;18(6):617-24.
9. Bernard F, Auquier P, Herrmann I, et al. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. Bone Marrow Transplant. 2014 May;49(5):709-16.
10. Sokos D.R., Berger M., Lazarus H. Intravenous Immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2002; 8:117-130.
11. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2005; 11(12):945-956.
12. Socie G et al. Chronic GVHD and health status in long-term survivors. Blood 2006:108.
13. Pavletic S., Lee S., Socie G., et al. Chronic graft versus host disease: implications of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials. Bone Marrow Transplantation 2006, 38(10):645-651.
14. Zeiser R, Burchert A, Lengerke et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8. Импакт-фактор 10,431.
15. Carenzio G, Gherardi P, Bardoni MT, et al. Rehabilitation of chronic graft versus host disease in children. A clinical series. Eura Medicophys. 2007 Dec;43(4):445-50.
16. Fiuza-Luces C, Garatachea N, Simpson RJ, et al. Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients. Exerc Immunol Rev. 2015;21:80-112.
17. Sullivan K.M. Graft-versus-Host disease. In: Forman S.J., et al., eds. Bone marrow transplantation. Boston: Blackwell scientific publications; 1994; 339-62.
18. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002; 100 (4): 1192-200.
19. Atkinson K., Horowitz M.M., Gale R.P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 245964.
20. Akpek G., Chinratanalab W., Lee L., et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biology of Blood and Marrow Transplantation 2003; 9, 46-51
21. Lee S.J., Vogelsang G., Flowers M., et al. Chronic graft-versus-host disease. New York: American Society for Blood and Marrow Transplantation; 2003.
22. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant.
23. Robin M, Guardiola P, Girinsky T, et al. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005. 15;80(5):634-42.
24. Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. Journal of clinical oncology 2005; Vol 23, 27:6596-6606.
25. Patriarca F, Skert C, Bonifazi F, et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006; 91(9):1268-72.
26. Palmas A, Tefferi A, Myers JL, et al. Late-onset non-infectious pulmonary complications after allogeneic bone marrow transplantation. Br J Hematology 1998; 100:680-687.
27. Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. Bone Marrow Transplant 1996; 17:1105-1111.
28. Socie G, Cahn JY, Carmelo J et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: Analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle. Br J Hematol 1997; 97:865-870.
29. Li X, Brazauskas R, Wang Z, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014 Apr;20(4):587-92.